Merck & Co Inc (MRK)
121.44
-0.08
(-0.07%)
USD |
NYSE |
Mar 18, 16:00
121.99
+0.55
(+0.45%)
After-Hours: 20:00
Merck Enterprise Value: 335.78B for March 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 15, 2024 | 335.78B |
March 14, 2024 | 333.22B |
March 13, 2024 | 337.40B |
March 12, 2024 | 338.67B |
March 11, 2024 | 338.95B |
March 08, 2024 | 340.80B |
March 07, 2024 | 342.04B |
March 06, 2024 | 341.43B |
March 05, 2024 | 339.10B |
March 04, 2024 | 342.19B |
March 01, 2024 | 349.56B |
February 29, 2024 | 350.04B |
February 28, 2024 | 352.68B |
February 27, 2024 | 354.80B |
February 26, 2024 | 354.32B |
February 23, 2024 | 355.87B |
February 22, 2024 | 355.39B |
February 21, 2024 | 352.50B |
February 20, 2024 | 350.60B |
February 16, 2024 | 351.66B |
February 15, 2024 | 348.50B |
February 14, 2024 | 346.67B |
February 13, 2024 | 345.69B |
February 12, 2024 | 345.46B |
February 09, 2024 | 345.74B |
Date | Value |
---|---|
February 08, 2024 | 348.67B |
February 07, 2024 | 350.85B |
February 06, 2024 | 349.36B |
February 05, 2024 | 347.59B |
February 02, 2024 | 348.17B |
February 01, 2024 | 348.09B |
January 31, 2024 | 333.91B |
January 30, 2024 | 336.01B |
January 29, 2024 | 335.05B |
January 26, 2024 | 333.89B |
January 25, 2024 | 332.14B |
January 24, 2024 | 328.98B |
January 23, 2024 | 331.41B |
January 22, 2024 | 330.37B |
January 19, 2024 | 329.00B |
January 18, 2024 | 328.12B |
January 17, 2024 | 327.08B |
January 16, 2024 | 327.99B |
January 12, 2024 | 328.34B |
January 11, 2024 | 327.84B |
January 10, 2024 | 328.93B |
January 09, 2024 | 327.84B |
January 08, 2024 | 325.18B |
January 05, 2024 | 324.77B |
January 04, 2024 | 324.24B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
176.33B
Minimum
Mar 23 2020
355.87B
Maximum
Feb 23 2024
244.29B
Average
225.15B
Median
Oct 29 2019
Enterprise Value Benchmarks
Amgen Inc | 197.76B |
Gilead Sciences Inc | 109.47B |
Johnson & Johnson | 387.42B |
Harpoon Therapeutics Inc (DELISTED) | 460.74M |
Moderna Inc | 31.09B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -1.226B |
Revenue (Quarterly) | 14.63B |
Total Expenses (Quarterly) | 16.34B |
EPS Diluted (Quarterly) | -0.48 |
Gross Profit Margin (Quarterly) | 73.26% |
Profit Margin (Quarterly) | -8.38% |
Earnings Yield | 0.12% |
Operating Earnings Yield | 0.96% |
Normalized Earnings Yield | 0.2626 |